~~<i id='1EA0496619'><strike id='1EA0496619'><tt id='1EA0496619'><pre id='1EA0496619'></pre></tt></strike></i>~~

Home» explore» focus

focus

author：hotspot 2025-10-06 13:03:45 Page View：78596

Novo Nordisk headquarters -- health coverage from STAT — LISELOTTE SABROE/Scanpix/AFP via Getty Images

LONDON — Novo Nordisk said Monday it would acquire the German firm Cardior Pharmaceuticals in a deal worth up to $1.1 billion, picking up additional drug candidates for its pipeline of cardiometabolic medicines.

Cardior focuses on targeting RNA to address the root causes of heart disease. Its lead candidate, known CDR132L, is in Phase 2 development as a treatment for health failure.

The companies did not disclose how much Novo was paying upfront for Cardior and how much would be based on future milestones being achieved. The deal is expected to close in the second quarter.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： A former Republican legislative candidate has been charged for his role in the US Capitol riot
Next article： How to save PrEP access — and even expand it

comprehensive

State Dept. review finds Biden bears some blame for Afghanistan failures

3:53HundredsofpeoplegathernearaU.S.AirForceC-17transportplaneattheperimeteroftheinternationalairport

SCOTUS to consider access to abortion pill mifepristone

AprotesterstandsoutsidetheSupremeCourtinWashingtoninApril2023.ShuranHuang/TheNewYorkTimesWASHINGTON—

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchennemusculardystrophyhistopathology.Dr.EdwinP.Ewing,Jr./CDCWhenIwasdiagnosedwithDuchennemuscular

After sickle

MollyFerguson/STATTheapprovalFridayofBluebirdBio’sgenetherapyforsicklecelldiseaseshouldhavebeenamome